Choksi Laboratories Ltd
Choksi Laboratories Ltd (CHOKSILA) last reported results for the quarter ended Jun 2026, with sales of ₹12.06 crore and net profit of ₹0.58 crore. The next scheduled event is an EGM on 17 Oct 2026. The stock last traded at ₹184, a market capitalisation of ₹128 crore, on a P/E of 67.5. Over the past 52 weeks the stock has ranged between ₹81.8 and ₹217. Figures are as of 6 Oct 2026 and are not real time.
Choksi Laboratories Ltd share price and key metrics
- Current price
- ₹184
- Market cap
- ₹128 cr
- Stock P/E
- 67.5
- Book value
- ₹36.7
- ROE
- 4.19%
- ROCE
- 9.44%
- Dividend yield
- 0.00%
- 52w high / low
- 217/81.8
Metrics as of 6 Oct 2026. Not real time.
Track Choksi Laboratories Ltd
Cruxal reads every Choksi Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Choksi Laboratories Ltd growth and returns
- 10 Years
- 6%
- 5 Years
- 12%
- 3 Years
- 10%
- TTM
- 11%
- 10 Years
- 3%
- 5 Years
- 19%
- 3 Years
- -14%
- TTM
- 27%
- 10 Years
- 29%
- 5 Years
- 52%
- 3 Years
- 49%
- 1 Year
- 5%
- 10 Years
- 3%
- 5 Years
- 5%
- 3 Years
- 5%
- Last Year
- 4%
Choksi Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹12.06 cr, up 7.3% from ₹11.24 cr a year earlier. Net profit was ₹0.58 cr, up 48.7% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 9.26 | 10.38 | 11.4 | 11.24 | 11.12 | 10.82 | 12.82 | 12.06 |
| Expenses | 6.9 | 7.84 | 7.9 | 8.34 | 8.19 | 8.16 | 9.18 | 8.78 |
| Operating profit | 2.36 | 2.54 | 3.5 | 2.9 | 2.93 | 2.66 | 3.64 | 3.28 |
| OPM % | 25.49% | 24.47% | 30.70% | 25.80% | 26.35% | 24.58% | 28.39% | 27.20% |
| Other income | 0.01 | 0.01 | 0.04 | 0 | 0.01 | 0.89 | 0.06 | 0.02 |
| Interest | 0.66 | 0.69 | 0.58 | 0.6 | 0.69 | 0.81 | 0.71 | 0.73 |
| Depreciation | 1.61 | 1.68 | 1.7 | 1.68 | 1.69 | 1.83 | 1.89 | 1.97 |
| Profit before tax | 0.1 | 0.18 | 1.26 | 0.62 | 0.56 | 0.91 | 1.1 | 0.6 |
| Tax % | 20.00% | 44.44% | 26.98% | 38.71% | 57.14% | 64.84% | 6.36% | 3.33% |
| Net profit | 0.08 | 0.11 | 0.92 | 0.39 | 0.24 | 0.31 | 1.03 | 0.58 |
| EPS (₹) | 0.11 | 0.16 | 1.32 | 0.56 | 0.34 | 0.45 | 1.48 | 0.83 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Choksi Laboratories Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 28.63 | 30.4 | 33.74 | 28.16 | 25.69 | 30.04 | 34.44 | 36.7 | 41.78 | 46.01 | 46.82 |
| Operating profit | 4.78 | 6.34 | 7.26 | 3.54 | 4.12 | 8.9 | 10.27 | 10.28 | 11.3 | 12.18 | 12.51 |
| OPM % | 16.70% | 20.86% | 21.52% | 12.57% | 16.04% | 29.63% | 29.82% | 28.01% | 27.05% | 26.47% | 26.72% |
| Net profit | 0.89 | 1.35 | 1.6 | -3.88 | -2.61 | 0.21 | 3.21 | 1.11 | 1.52 | 1.96 | 2.16 |
| EPS (₹) | 1.28 | 1.94 | 2.30 | -5.57 | -3.75 | 0.30 | 4.61 | 1.59 | 2.18 | 2.81 | 3.10 |
TTM is the trailing twelve months to the most recent quarter.
Choksi Laboratories Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 |
| Reserves | 14.16 | 15.43 | 17.04 | 13.26 | 10.78 | 10.94 | 14.14 | 15.25 | 16.64 | 18.61 |
| Borrowings | 11.20 | 12.43 | 17.05 | 31.64 | 39.15 | 37.29 | 32.41 | 30.87 | 29.15 | 34.17 |
| Other liabilities | 8.32 | 9.85 | 14.28 | 13.14 | 9.48 | 9.22 | 6.84 | 8.86 | 12.57 | 12.17 |
| Total liabilities | 40.65 | 44.68 | 55.34 | 65.01 | 66.38 | 64.42 | 60.36 | 61.95 | 65.33 | 71.92 |
| Fixed assets | 22.23 | 28.62 | 34.81 | 33.08 | 50.32 | 46.56 | 44.83 | 43.43 | 47.61 | 51.55 |
| CWIP | 4.28 | 0.00 | 3.23 | 13.06 | 0.50 | 1.67 | 0.31 | 2.99 | 0.00 | 0.40 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other assets | 14.14 | 16.06 | 17.30 | 18.87 | 15.56 | 16.19 | 15.22 | 15.53 | 17.72 | 19.97 |
| Total assets | 40.65 | 44.68 | 55.34 | 65.01 | 66.38 | 64.42 | 60.36 | 61.95 | 65.33 | 71.92 |
As reported by the company. Total assets equal total liabilities by construction.
Choksi Laboratories Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 6.57 | 6.25 | 6.91 | 2.87 | 5.90 | 7.88 | 8.25 | 11.55 | 11.78 | 7.86 |
| Cash from investing | -1.88 | -4.92 | -9.76 | -13.76 | -7.65 | -2.71 | -0.71 | -6.65 | -7.61 | -7.07 |
| Cash from financing | -4.89 | -0.94 | 2.13 | 11.09 | 1.63 | -5.07 | -7.61 | -4.58 | -4.22 | -1.20 |
| Net cash flow | -0.20 | 0.39 | -0.72 | 0.20 | -0.12 | 0.10 | -0.07 | 0.32 | -0.04 | -0.41 |
| Free cash flow | 4.18 | 1.30 | -3.09 | -11.18 | -2.18 | 5.05 | 7.34 | 4.54 | 4.09 | 0.62 |
| CFO / operating profit | 124% | 124% | 137% | 111% | 68% | 75% | 73% | 117% | 122% | 69% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Choksi Laboratories Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 7.33% | 10.51% | 10.09% | -1.48% | 0.00% | 6.40% | 9.16% | 8.87% | 9.20% | 9.44% |
| Debtor days | 112.19 | 118.62 | 95.09 | 90.60 | 115.94 | 125.03 | 112.87 | 103.33 | 98.46 | 116.85 |
| Inventory days | 28.27 | 30.50 | 37.89 | 20.28 | 15.62 | 46.09 | 34.68 | 51.33 | 65.94 | 25.47 |
| Days payable | 591.13 | 594.31 | 660.70 | 723.24 | 685.97 | 741.06 | 297.29 | 560.33 | 639.34 | 594.19 |
| Cash conversion cycle | -450.67 | -445.18 | -527.72 | -612.36 | -554.41 | -569.95 | -149.73 | -405.67 | -474.95 | -451.87 |
| Working capital days | -23.71 | -18.37 | 28.02 | 21.13 | -49.73 | -23.33 | 11.66 | -49.13 | -71.29 | -35.14 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Choksi Laboratories Ltd shareholding pattern
Promoters held 31.48% at Sep 2026, broadly unchanged since Sep 2025. FIIs 10.01%.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 31.48% | 31.48% | 31.48% | 31.48% | 31.48% | 31.48% | 31.48% | 31.48% |
| FIIs | 0.00% | 1.94% | 4.31% | 5.69% | 5.69% | 6.03% | 7.02% | 10.01% |
| Public | 68.52% | 66.58% | 64.22% | 62.83% | 62.83% | 62.49% | 61.49% | 58.51% |
| No. of shareholders | 4,466 | 4,162 | 4,167 | 4,067 | 4,057 | 4,011 | 3,945 | 3,829 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Choksi Laboratories Ltd events
The next scheduled event is an EGM on 17 Oct 2026.
- EGMApproval for preferential issue of 3,50,000 convertible warrants to promoters
- Preferential issueApproval for preferential issuance of 3,50,000 convertible equity warrants to promoters
See the full results calendar for every Indian company reporting in the next 30 days.
Choksi Laboratories Ltd corporate filings
- Submission of compliance certificate under Regulation 74(5) of SEBI (DP) Regulation for the quarter ended 30.09.2026Company Updatelow impact
- Intimation for closure of trading window w.e.f. 01.10.2026Insider Trading / SASTlow impact
- Choksi Laboratories Ltd announces newspaper publication of EGM noticeCompany Updatelow impact
Cruxal's analysis: Choksi Laboratories Ltd has submitted the mandatory newspaper publication regarding the…
Read the full analysis - Choksi Laboratories Announces Preferential Issue of 3.50 Lakh Convertible Warrants to Promoters to Raise INR 6.19 CroreAGM/EGMhigh impact
Cruxal's analysis: Choksi Laboratories Limited has announced a preferential issue of 3.50 lakh convertible…
Read the full analysis - Choksi Laboratories Limited Announces Successful Conclusion of 33rd Annual General Meeting and Approval of All ResolutionsAGM/EGMlow impact
Cruxal's analysis: Choksi Laboratories Limited has successfully concluded its 33rd Annual General Meeting…
Read the full analysis - Choksi Laboratories Limited Announces Preferential Issue of Warrants to Promoters Aggregating INR 6.19 CroreBoard Meetinghigh impact
Cruxal's analysis: Choksi Laboratories Limited has approved the issuance of up to 3.50 lakh convertible…
Read the full analysis - Choksi Laboratories Limited concludes 33rd Annual General Meeting; re-appoints key leadershipAGM/EGMlow impact
Cruxal's analysis: Choksi Laboratories Limited has successfully concluded its 33rd Annual General Meeting…
Read the full analysis - Choksi Laboratories Limited announces board meeting to consider fund-raising via preferential issueBoard Meetinghigh impact
Cruxal's analysis: Choksi Laboratories Limited has scheduled a board meeting for September 19, 2026, to…
Read the full analysis - Choksi Laboratories Ltd submits newspaper clipping for 33rd Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Choksi Laboratories Ltd has filed the mandatory newspaper advertisement regarding the…
Read the full analysis - Choksi Laboratories Limited schedules 33rd Annual General Meeting for September 18, 2026Company Updatelow impact
Cruxal's analysis: Choksi Laboratories Limited has issued a formal intimation regarding the dispatch of its…
Read the full analysis - Choksi Laboratories Ltd submits Annual Report for the Financial Year 2025-26Otherslow impact
Cruxal's analysis: Choksi Laboratories Ltd has submitted its Annual Report for the fiscal year 2025-26 as…
Read the full analysis - Choksi Laboratories Limited Announces 33rd Annual General Meeting for September 18, 2026AGM/EGMlow impact
Cruxal's analysis: Choksi Laboratories Limited has issued the formal notice for its 33rd Annual General…
Read the full analysis - Choksi Laboratories Ltd announces upcoming USFDA inspectionCompany Updatemedium impact
Cruxal's analysis: Choksi Laboratories has provided an intimation under Regulation 30 of SEBI (LODR) 2015…
Read the full analysis - Choksi Laboratories Ltd announces 33rd Annual General Meeting details via newspaper publicationCompany Updatelow impact
Cruxal's analysis: Choksi Laboratories Ltd has submitted the required newspaper clippings regarding the…
Read the full analysis - Choksi Laboratories Limited Reports Q1 FY27 Financial Results: Revenue at 12.87 Crore with Net Profit of 0.92 CroreCompany Updatelow impact
Cruxal's analysis: Choksi Laboratories Limited has released its unaudited financial results for the quarter…
Read the full analysis - Choksi Laboratories Limited announces re-appointment of Internal Auditor for FY 2026-27Company Updatelow impact
Cruxal's analysis: Choksi Laboratories Limited has formally disclosed the re-appointment of M/s Tanmay V…
Read the full analysis - Choksi Laboratories Limited announces re-appointment of Ms. Himika Choksi as Whole Time DirectorCompany Updatelow impact
Cruxal's analysis: Choksi Laboratories Limited has formally announced the re-appointment of Ms. Himika…
Read the full analysis - Choksi Laboratories Limited reports Q1 FY2027 results with 7.4% YoY revenue growth but significant sequential profit contractionResultmedium impact
Cruxal's analysis: Choksi Laboratories Limited reported revenue from operations of 12.06 crore for the…
Read the full analysis - Choksi Laboratories reports Q1 FY27 results with 51% YoY profit growth; announces AGM and leadership re-appointmentBoard Meetinghigh impact
Cruxal's analysis: Choksi Laboratories Limited reported a steady performance for the quarter ended 30th June…
Read the full analysis - Choksi Laboratories Limited schedules Board Meeting for 13th August 2026 to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Choksi Laboratories Limited has formally intimated the BSE regarding a Board of Directors…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.